TheraRadar

Pharma Intelligence, Simplified

Competitive Landscape by Indication

151 indications, 101,562 trials mapped

Oncology

39,733 trials
Solid Tumor (Advanced)
6371 trials 534 Ph3
Merck, Sichuan Baili Pharmaceutical Co., Ltd., Eli Lilly
Breast Cancer
2529 trials 441 Ph3
AstraZeneca, Roche, Pfizer
Non-Hodgkin Lymphoma
2519 trials 221 Ph3
Roche, Genmab, Merck
NSCLC
2438 trials 392 Ph3
AstraZeneca, Merck, Roche
ALL
1934 trials 292 Ph3
Novartis, AstraZeneca, Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer
1795 trials 244 Ph3
AstraZeneca, AbbVie, Revolution Medicines, Inc.
Prostate Cancer
1607 trials 249 Ph3
Novartis, Johnson & Johnson, AstraZeneca
AML
1255 trials 114 Ph3
AbbVie, Taiho Oncology, Inc., Kura Oncology, Inc.
Multiple Myeloma
1197 trials 142 Ph3
Johnson & Johnson, GSK, AbbVie
Pancreatic Cancer
1116 trials 103 Ph3
AstraZeneca, Revolution Medicines, Inc., Seagen, a wholly owned subsidiary of Pfizer
Melanoma
1078 trials 99 Ph3
Merck, Pfizer, Novartis
Hepatocellular Carcinoma
999 trials 142 Ph3
AstraZeneca, Roche, Akeso
Hematologic Malignancies
989 trials 86 Ph3
Johnson & Johnson, Novartis, Orca Biosystems, Inc.
Ovarian Cancer
975 trials 116 Ph3
AstraZeneca, AbbVie, Merck
Head and Neck Cancer
939 trials 77 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca, Pfizer
Lung Cancer (General)
919 trials 120 Ph3
Chongqing Precision Biotech Co., Ltd, AstraZeneca, Avistone Biotechnology Co., Ltd.
Sarcoma
892 trials 62 Ph3
Eli Lilly, Hansoh BioMedical R&D Company, Philogen S.p.A.
Bladder Cancer
821 trials 121 Ph3
Merck, AstraZeneca, Pfizer
Gastric Cancer
805 trials 120 Ph3
AstraZeneca, Astellas Pharma Global Development, Inc., Chongqing Precision Biotech Co., Ltd
MDS
715 trials 58 Ph3
Bristol-Myers Squibb, Takeda, Taiho Oncology, Inc.
Esophageal Cancer
704 trials 114 Ph3
AstraZeneca, Merck, AbbVie
Glioblastoma
628 trials 43 Ph3
Novartis, Philogen S.p.A., GT Medical Technologies, Inc.
Brain Tumor
618 trials 51 Ph3
Jazz Pharmaceuticals, Pfizer, InSightec
Renal Cell Carcinoma
544 trials 50 Ph3
Merck, Bristol-Myers Squibb, Exelixis
SCLC
543 trials 74 Ph3
Amgen, AstraZeneca, Merck
Triple Negative Breast Cancer
517 trials 55 Ph3
Gilead, Novartis, Eli Lilly
Squamous Cell Carcinoma
495 trials 48 Ph3
Regeneron, Merck, Alentis Therapeutics AG
Hodgkin Lymphoma
491 trials 31 Ph3
Merck, AbbVie, Sichuan Baili Pharmaceutical Co., Ltd.
Cholangiocarcinoma
468 trials 45 Ph3
AstraZeneca, Eli Lilly, TransThera Sciences (Nanjing), Inc.
Cervical Cancer
439 trials 72 Ph3
AstraZeneca, Shanghai Bovax Biotechnology Co., Ltd., Merck
CLL
432 trials 49 Ph3
BeOne Medicines, AbbVie, Acerta Pharma BV
Neuroendocrine Tumors
403 trials 79 Ph3
Vertex Pharmaceuticals Incorporated, Crinetics Pharmaceuticals Inc., ITM Solucin GmbH
Endometrial Cancer
366 trials 43 Ph3
AstraZeneca, Merck, Genmab
Myelofibrosis
228 trials 30 Ph3
Novartis, Bristol-Myers Squibb, Incyte Corporation
Mesothelioma
218 trials 14 Ph3
Novartis, NGM Biopharmaceuticals, Inc, Seagen, a wholly owned subsidiary of Pfizer
CML
204 trials 18 Ph3
Novartis, Shenzhen TargetRx, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Thyroid Cancer
166 trials 25 Ph3
Eli Lilly, Exelixis, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER2+ Breast Cancer
148 trials 31 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., Shanghai JMT-Bio Inc., Roche
HER2- Breast Cancer
139 trials 15 Ph3
AstraZeneca, BeiGene, Olema Pharmaceuticals, Inc.
Merkel Cell Carcinoma
89 trials 6 Ph3
TuHURA Biosciences, Inc., ImmunityBio, Inc., Neonc Technologies, Inc.

CNS

6,651 trials
Major Depression
1007 trials 245 Ph3
Neurocrine Biosciences, Johnson & Johnson, Neumora Therapeutics, Inc.
Alzheimer's Disease
966 trials 188 Ph3
Eli Lilly, Bristol-Myers Squibb, Roche
Multiple Sclerosis
767 trials 188 Ph3
Roche, Novartis, Sanofi
Parkinson's Disease
559 trials 80 Ph3
iRegene Therapeutics Co., Ltd., Luye Pharma Group Ltd., Roche
Schizophrenia
426 trials 117 Ph3
Neurocrine Biosciences, Luye Pharma Group Ltd., Bristol-Myers Squibb
Opioid Use Disorder
365 trials 73 Ph3
Indivior Inc., Go Medical Industries Pty Ltd, Akyso Therapeutics, LLC
ALS
354 trials 79 Ph3
Amylyx Pharmaceuticals Inc., Biogen, XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Migraine
346 trials 156 Ph3
AbbVie, Pfizer, H. Lundbeck A/S
Epilepsy
294 trials 88 Ph3
UCB Biopharma SRL, Xenon Pharmaceuticals Inc., SK Life Science, Inc.
Alcohol Use Disorder
277 trials 42 Ph3
Eli Lilly, Afasci Inc, Pop Test Oncology LLC
Anxiety
259 trials 51 Ph3
VistaGen Therapeutics, Inc., Definium Therapeutics US, Inc., Intra-Cellular Therapies, Inc.
Neuropathy
237 trials 64 Ph3
argenx, Sanofi, Takeda
Autism Spectrum Disorder
215 trials 44 Ph3
Intra-Cellular Therapies, Inc., Bristol-Myers Squibb, MapLight Therapeutics
PTSD
183 trials 37 Ph3
Oui Therapeutics, Inc., Senseye, Inc., Otsuka Medical Devices Co., Ltd. Japan
ADHD
161 trials 65 Ph3
Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc., Boehringer Ingelheim
Bipolar Disorder
130 trials 40 Ph3
Intra-Cellular Therapies, Inc., Bristol-Myers Squibb, Xenon Pharmaceuticals Inc.
Huntington's Disease
54 trials 9 Ph3
Roche, Novartis, Skyhawk Therapeutics, Inc.
OCD
51 trials 6 Ph3
Vericel Corporation, Biohaven Pharmaceuticals, Inc.

Click any indication to see full competitive landscape (all sponsors, trials, phases).

Data: ClinicalTrials.gov | Mapping: Indication Taxonomy